aTyr Pharma Inc
ATYR
NASDAQ
Biotechnology
$0.56
USD
+0.01 (+1.08%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $56.90M
Volume 648.1K
Revenue
$190,000
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-70.03M
TTM
-10.4%
YoY
Operating Cash Flow
$-59.08M
TTM
+4.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 |
Selling, General & Administrative | 4.0 | 4.9 | 4.8 | 3.9 | 4.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 15.8 | 20.3 | 26.9 | 14.8 | 11.4 |
Operating Income | -15.8 | -20.3 | -26.7 | -14.8 | -11.4 |
EBITDA | -15.6 | -20.1 | -26.6 | -14.6 | -11.3 |
Other Income / Expense | 0.9 | 0.8 | 1.0 | 0.8 | 0.6 |
Total Other Income / Expense | 0.9 | 0.8 | 1.0 | 0.8 | 0.6 |
Income Before Income Taxes | -14.9 | -19.5 | -25.7 | -14.0 | -10.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -14.9 | -19.5 | -25.7 | -14.0 | -10.8 |
Consolidated Net Income / Loss | -14.9 | -19.5 | -25.7 | -14.0 | -10.8 |
Net Income Attributable to Common Shareholders | -14.9 | -19.5 | -25.7 | -14.0 | -10.8 |
Basic EPS | -$0.17 | -$0.22 | -$0.26 | -$0.14 | -$0.11 |
Diluted EPS | -$0.17 | -$0.22 | -$0.26 | -$0.14 | -$0.11 |
Basic Shares Outstanding | 86.5M | 90.1M | 97.2M | 98.2M | 98.0M |
Diluted Shares Outstanding | 86.5M | 90.1M | 97.2M | 98.2M | 98.0M |